- Home
- CPS vs NGNE Comparison
CPS vs NGNE Comparison
Compare CPS & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CPS
- NGNE
- Stock Information
- Founded
- CPS 1960
- NGNE 2003
- Country
- CPS United States
- NGNE United States
- Employees
- CPS N/A
- NGNE N/A
- Industry
- CPS Auto Parts:O.E.M.
- NGNE Biotechnology: Pharmaceutical Preparations
- Sector
- CPS Consumer Discretionary
- NGNE Health Care
- Exchange
- CPS Nasdaq
- NGNE Nasdaq
- Market Cap
- CPS 462.2M
- NGNE 426.6M
- IPO Year
- CPS N/A
- NGNE N/A
- Fundamental
- Price
- CPS $28.07
- NGNE $31.80
- Analyst Decision
- CPS Buy
- NGNE Strong Buy
- Analyst Count
- CPS 2
- NGNE 8
- Target Price
- CPS $26.50
- NGNE $44.75
- AVG Volume (30 Days)
- CPS 230.1K
- NGNE 241.5K
- Earning Date
- CPS 10-30-2025
- NGNE 11-18-2025
- Dividend Yield
- CPS N/A
- NGNE N/A
- EPS Growth
- CPS N/A
- NGNE N/A
- EPS
- CPS 1.84
- NGNE N/A
- Revenue
- CPS $2,729,297,000.00
- NGNE N/A
- Revenue This Year
- CPS $2.31
- NGNE N/A
- Revenue Next Year
- CPS $3.69
- NGNE N/A
- P/E Ratio
- CPS $15.26
- NGNE N/A
- Revenue Growth
- CPS N/A
- NGNE N/A
- 52 Week Low
- CPS $10.38
- NGNE $6.88
- 52 Week High
- CPS $40.67
- NGNE $74.49
- Technical
- Relative Strength Index (RSI)
- CPS 31.60
- NGNE 57.46
- Support Level
- CPS $37.11
- NGNE $27.28
- Resistance Level
- CPS $39.75
- NGNE $35.47
- Average True Range (ATR)
- CPS 1.90
- NGNE 3.29
- MACD
- CPS -0.83
- NGNE -0.32
- Stochastic Oscillator
- CPS 1.18
- NGNE 45.26
About CPS Cooper-Standard Holdings Inc.
Cooper-Standard Holdings Inc is engaged in the manufacture of sealing and fluid handling systems (consisting of fuel and brake delivery systems and fluid transfer systems). Its products are designed for passenger vehicles and light trucks that are manufactured by automotive original equipment manufacturers (OEMs) and replacement markets. It has two reportable segments: Sealing Systems and Fluid Handling Systems. The group's geographic regions are North America, Europe, Asia Pacific, and South America.
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.